State Key Laboratory of Southwestern Chinese Medicine Resources; Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Key Laboratory of Quality Control and Efficacy Evaluation of Traditional Chinese Medicine Formula Granules, Sichuan New Green Medicine Science and Technology Development Co., Ltd., Pengzhou, 610031, China.
State Key Laboratory of Southwestern Chinese Medicine Resources; Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
J Ethnopharmacol. 2021 Oct 5;278:114281. doi: 10.1016/j.jep.2021.114281. Epub 2021 Jun 1.
Spleen-Yang deficiency (SYD) is one of the primary causes of many digestive diseases, such as ulcerative colitis (UC), and irritable bowel syndrome (IBS), but its endogenous metabolic characteristics are still unclear. Fuzi Lizhong pill (FLZP) is well-known for its powerful capacity for treating SYD; however, its mechanisms require further study.
Herein, our present study aimed to investigate the essence of SYD from the perspective of metabolomics, and tried to reveal the anti-SYD action mechanisms of FLZP.
Firstly, the compound factor modeling method with the principle of "indiscipline in diet + excessive fatigue + intragastric administration of Senna water extracts" was used to establish Sprague Dawley (SD) rats as SYD model. Then, the visceral index, motilin (MTL), malonaldehyde (MDA), Interleukin 1 alpha (IL-1α), and Interleukin 6 (IL-6) levels were used to verify the anti-SYD effect of FLZP. In addition, serum samples were analyzed by UPLC-QE/MS metabolomics technique. Finally, the metabolic pathways associated with specific biomarkers were analyzed to research the possible mechanism underlying the action of FLZP.
The expression of MTL, MDA, IL-1α, and IL-6 were regulated by FLZP, which suggested that it has relieved diarrhea and gastrointestinal motility disorder caused by SYD and had an anti-peroxidation, anti-inflammatory, and immune regulation effect. A total of 75 metabolites were found to be the potential biomarkers of SYD. Moreover, FLZP regulates 21 metabolites and 10 vital pathways including the tricarboxylic acid (TCA) cycle, sphingolipid metabolism, and histidine metabolism.
SYD primarily causes disorders of amino acid metabolism, lipid metabolism, carbohydrate metabolism, metabolism of cofactors and vitamins, nucleotide metabolism, and translation. In addition, FLZP regulated carbohydrate, lipid, and amino acid metabolisms, gastrointestinal motility, digestive juice secretion, immune regulation, as well as antioxidant effects. Hence, FLZP had a good therapeutic effect on treatment of SYD. It might be a promising therapeutic agent for the treatment of SYD-related diseases.
脾阳虚(SYD)是许多消化系统疾病(如溃疡性结肠炎(UC)和肠易激综合征(IBS))的主要病因之一,但它的内源性代谢特征尚不清楚。附子理中丸(FLZP)以其强大的治疗 SYD 能力而闻名;然而,其机制仍需要进一步研究。
本研究旨在从代谢组学的角度探讨 SYD 的本质,并试图揭示 FLZP 的抗 SYD 作用机制。
首先,采用“饮食不规律+过度疲劳+胃内给予番泻叶水提取物”的复合因素造模方法,建立 SYD 模型大鼠。然后,利用内脏指数、胃动素(MTL)、丙二醛(MDA)、白细胞介素 1α(IL-1α)和白细胞介素 6(IL-6)水平来验证 FLZP 的抗 SYD 作用。此外,采用 UPLC-QE/MS 代谢组学技术分析血清样本。最后,分析与特定生物标志物相关的代谢途径,以研究 FLZP 作用的可能机制。
FLZP 调节了 MTL、MDA、IL-1α 和 IL-6 的表达,提示其缓解了 SYD 引起的腹泻和胃肠动力障碍,具有抗过氧化、抗炎和免疫调节作用。共发现 75 种潜在的 SYD 生物标志物代谢物。此外,FLZP 调节了 21 种代谢物和 10 条重要代谢途径,包括三羧酸(TCA)循环、鞘脂代谢和组氨酸代谢。
SYD 主要导致氨基酸代谢、脂质代谢、碳水化合物代谢、辅酶和维生素代谢、核苷酸代谢和翻译的紊乱。此外,FLZP 调节了碳水化合物、脂质和氨基酸代谢、胃肠动力、消化液分泌、免疫调节以及抗氧化作用。因此,FLZP 对治疗 SYD 有良好的疗效。它可能是治疗 SYD 相关疾病的一种有前途的治疗药物。